Targeting TSLP in Asthma

References

• Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783–800. doi:10.1016/S0140-6736(17)33311-1
   PubMed Web of Science ®Google Scholar
• Dorey-Stein ZL, Shenoy KV. Tezepelumab as an emerging therapeutic option for the treatment of severe asthma: evidence to date. Drug Des Devel Ther. 2021;15:331–338. doi:10.2147/DDDT.S250825
   PubMed Web of Science ®Google Scholar
• Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers. 2015;1(1):15025. doi:10.1038/nrdp.2015.25
   PubMed Web of Science ®Google Scholar
• Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1–12. doi:10.1016/j.jaci.2019.05.031
   PubMed Web of Science ®Google Scholar
• Kupczyk M, Dahlén B, Sterk PJ, et al. BIOAIR Investigators. Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy. 2014;69(9):1198–1204. doi:10.1111/all.12445
   PubMed Web of Science ®Google Scholar
• de Llano LP, Rivas DD, Cid NB, Robles IM. Phenotype-guided asthma therapy: an alternative approach to guidelines. J Asthma Allergy. 2021;14:207–217. doi:10.2147/JAA.S266999
   PubMed Web of Science ®Google Scholar
• Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75(3):311–325. doi:10.1111/all.13985
   PubMed Web of Science ®Google Scholar
• Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry. Chest. 2020;157(4):790–804. doi:10.1016/j.chest.2019.10.053
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777–792. doi:10.1080/14728222.2020.1783242
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention; 2021. Available from. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Accessed October 7, 2021.
   Google Scholar
• Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. doi:10.3389/fped.2019.00246
   PubMed Web of Science ®Google Scholar
• Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075–2088. doi:10.1080/03007995.2018.1505352
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. doi:10.1186/s12931-020-01505-x
   PubMed Web of Science ®Google Scholar
• Gallelli L, Busceti MT, Vatrella A, Maselli R, Pelaia G. Update on anticytokine treatment for asthma. Biomed Res Int. 2013;2013:104315. doi:10.1155/2013/104315
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Matera MG, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2020;6(1):47–66. doi:10.1007/s41030-019-00109-1
   PubMedGoogle Scholar
• Caminati M, Senna G. Uncontrolled severe asthma: starting from the unmet needs. Curr Med Res Opin. 2019;35(2):175–177. doi:10.1080/03007995.2018.1528218
   PubMed Web of Science ®Google Scholar
• Tan L, Reibman J, Ambrose C, et al. Clinical and economic burden of patients with uncontrolled severe asthma with low blood eosinophil levels in the United States. J Allergy Clin Immunol. 2021;147(2 suppl):AB47. doi:10.1016/j.jaci.2020.12.199
   Web of Science ®Google Scholar
• Comeau MR, Ziegler SF. The influence of TSLP on the allergic response. Mucosal Immunol. 2010;3(2):138–147. doi:10.1038/mi.2009.134
   PubMed Web of Science ®Google Scholar
• Kitajima M, Lee H-C, Nakayama T, Ziegler SF. TSLP enhances the function of helper type 2 cells. Eur J Immunol. 2011;41(7):1862–1871. doi:10.1002/eji.201041195
   PubMed Web of Science ®Google Scholar
• Holgate ST. The airway epithelium is central to the pathogenesis of asthma. Allergol Int. 2008;57(1):1–10. doi:10.2332/allergolint.R-07-154
   PubMedGoogle Scholar
• Bartemes KR, Kita H. Dynamic role of epithelium-derived cytokines in asthma. Clin Immunol. 2012;143(3):222–235. doi:10.1016/j.clim.2012.03.001
   PubMed Web of Science ®Google Scholar
• Friend SL, Hosier S, Nelson A, Foxworthe D, Williams DE, Farr A. A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells. Exp Hematol. 1994;22(3):321–328.
   PubMed Web of Science ®Google Scholar
• Patel NN, Kohanski MA, Maina IW, Workman AD, Herbert DR, Cohen NA. Sentinels at the wall: epithelial-derived cytokines serve as triggers of upper airway type 2 inflammation. Int Forum Allergy Rhinol. 2019;9(1):93–99. doi:10.1002/alr.22206
   PubMed Web of Science ®Google Scholar
• Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol. 2010;11(4):289–293. doi:10.1038/ni.1852
   PubMed Web of Science ®Google Scholar
• Headley MB, Zhou B, Shih WX, Aye T, Comeau MR, Ziegler SF. TSLP conditions the lung immune environment for the generation of pathogenic innate and antigen-specific adaptive immune responses. J Immunol. 2009;182(3):1641–1647. doi:10.4049/jimmunol.182.3.1641
   PubMed Web of Science ®Google Scholar
• Redhu NS, Gounni AS. Function and mechanisms of TSLP/TSLPR complex in asthma and COPD. Clin Exp Allergy. 2012;42(7):994–1005. doi:10.1111/j.1365-2222.2011.03919.x
   PubMed Web of Science ®Google Scholar
• Ying S, O’Connor B, Ratoff J, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol. 2005;174(12):8183–8190. doi:10.4049/jimmunol.174.12.8183
   PubMed Web of Science ®Google Scholar
• Ying S, O’Connor B, Ratoff J, et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181(4):2790–2798. doi:10.4049/jimmunol.181.4.2790
   PubMed Web of Science ®Google Scholar
• Li Y, Wang W, Lv Z, et al. Elevated expression of IL-33 and TSLP in the airways of human asthmatics in vivo: a potential biomarker of severe refractory disease. J Immunol. 2018;200(7):2253–2262. doi:10.4049/jimmunol.1701455
   PubMed Web of Science ®Google Scholar
• Ko H-K, Cheng S-L, Lin C-H, et al. Blood tryptase and thymic stromal lymphopoietin levels predict the risk of exacerbation in severe asthma. Sci Rep. 2021;11(1):8425. doi:10.1038/s41598-021-86179-1
   PubMed Web of Science ®Google Scholar
• Zhou B, Comeau MR, De Smedt T, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol. 2005;6(10):1047–1053. doi:10.1038/ni1247
   PubMed Web of Science ®Google Scholar
• Ziegler SF, Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H. The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol. 2013;66:129–155. doi: 10.1016/B978-0-12-404717-4.00004-4
   PubMedGoogle Scholar
• Kabata H, Flamar A-L, Mahlakõiv T, et al. Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation. Mucosal Immunol. 2020;13(4):626–636. doi:10.1038/s41385-020-0266-x
   PubMed Web of Science ®Google Scholar
• He J-Q, Hallstrand TS, Knight D, et al. A thymic stromal lymphopoietin gene variant is associated with asthma and airway hyperresponsiveness. J Allergy Clin Immunol. 2009;124(2):222–229. doi:10.1016/j.jaci.2009.04.018
   PubMed Web of Science ®Google Scholar
• Sun Y, Wei X, Deng J, et al. Association of IL1RL1 rs3771180 and TSLP rs1837253 variants with asthma in the Guangxi Zhuang population in China. J Clin Lab Anal. 2019;33(6):e22905. doi:10.1002/jcla.22905
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–2110. doi:10.1056/NEJMoa1402895
   PubMed Web of Science ®Google Scholar
• Gauvreau G, Hohlfeld J, Boulet L-P, et al. Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients. Eur Respir J. 2020;56:3690. doi:10.1183/13993003.congress-2020.3690
   Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Novartis clinical trial results website. Protocol Number CCSJ117X2201. Available from: https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17681. Accessed October 8, 2021.
   Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946. doi:10.1056/NEJMoa1704064
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Colice G, Griffiths JM, et al. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21(1):266. doi:10.1186/s12931-020-01526-6
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975
   PubMed Web of Science ®Google Scholar
• Bonini M, Di Paolo M, Bagnasco D, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29(156):190137. doi:10.1183/16000617.0137-2019
   PubMed Web of Science ®Google Scholar
• Corren J, Ambrose CS, Sałapa K, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J Allergy Clin Immunol Pract. 2021;9(12):4334–4342.e6. doi:10.1016/j.jaip.2021.07.045
   PubMed Web of Science ®Google Scholar
• Israel E, Chupp G, Colice G, et al. Tezepelumab efficacy according to US omalizumab eligibility: results from the NAVIGATOR phase 3 study. Abstract presented at: American College of Allergy, Asthma & Immunology (ACAAI) 2021 Annual Scientific Meeting; November 4–8; 2021; New Orleans, Louisiana, USA.
   Google Scholar
• Corren J, Menzies-Gow A, Ambrose CS, et al. The effect of tezepelumab in patients with allergic and non-allergic asthma: results from the NAVIGATOR phase 3 study. Abstract presented at: European Academy of Allergy and Clinical Immunology (EAACI) 2021 Hybrid Conference; July 1–12; 2021; Madrid, Spain (Digital); Krakow, Poland (Hybrid).
   Google Scholar
• Emson C, Corren J, Sałapa K, Hellqvist Å, Parnes JR, Colice G. Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the phase 2b PATHWAY study. J Asthma Allergy. 2021;14:91–99. doi:10.2147/JAA.S288260
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Brightling C, Ambrose C, et al. Effect of tezepelumab in oral corticosteroid-dependent patients with severe asthma: results from the phase 3 NAVIGATOR study. Am J Respir Crit Care Med. 2021;203:A1442.
   PubMed Web of Science ®Google Scholar
• Gerhardsson de Verdier M, Gustafson P, McCrae C, Edsbäcker S, Johnston N. Seasonal and geographic variations in the incidence of asthma exacerbations in the United States. J Asthma. 2017;54(8):818–824. doi:10.1080/02770903.2016.1277538
   PubMed Web of Science ®Google Scholar
• Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1–11. doi:10.2147/JAA.S286036
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Colice G, Griffiths JM, et al. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020;21(1):264. doi:10.1186/s12931-020-01503-z
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Menzies-Gow A, Brightling CE, et al. SOURCE study group. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022;S2213–S2600(21):00537-3. doi:10.1016/S2213-2600(21)00537-3
   Web of Science ®Google Scholar
• Bourdin A, Menzies-Gow A, Chupp G, et al. Reductions in asthma exacerbation-related hospitalizations and emergency department visits in patients with severe, uncontrolled asthma treated with tezepelumab: results from the phase 3 NAVIGATOR study. Am J Respir Crit Care Med. 2021;203:A1203.
   PubMed Web of Science ®Google Scholar
• Corren J, Chen S, Callan L, Gil EG. The effect of tezepelumab on hospitalizations and emergency department visits in patients with severe asthma. Ann Allergy Asthma Immunol. 2020;125(2):211–214. doi:10.1016/j.anai.2020.05.020
   PubMed Web of Science ®Google Scholar
• Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol. 2012;129(3 suppl):S65–S87. doi:10.1016/j.jaci.2011.12.986
   PubMed Web of Science ®Google Scholar
• Braido F, Baiardini I, Canonica GW. Patient-reported outcomes in asthma clinical trials. Curr Opin Pulm Med. 2018;24(1):70–77. doi:10.1097/MCP.0000000000000440
   PubMed Web of Science ®Google Scholar
• Diver S, Khalfaoui L, Emson C, et al. CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299–1312. doi:10.1016/S2213-2600(21)00226-5
   PubMed Web of Science ®Google Scholar
• Shen Q, von Maltzahn R, Nelsen L, Revicki D. Psychometric properties of the asthma symptom index in patients with severe asthma. J Allergy Clin Immunol Pract. 2021;9(1):400–409.e1. doi:10.1016/j.jaip.2020.08.019
   PubMed Web of Science ®Google Scholar
• Corren J, Garcia Gil E, Griffiths JM, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021;126(2):187–193. doi:10.1016/j.anai.2020.10.008
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Maltais F, Rouleau M, Guímont C. French-Canadian version of the Chronic Respiratory and St George’s respiratory questionnaires: an assessment of their psychometric properties in patients with chronic obstructive pulmonary disease. Can Respir J. 2004;11(7):480–486. doi:10.1155/2004/702421
   PubMedGoogle Scholar
• Luc F, Prieur E, Whitmore GA, Gibson PG, Vandemheen KL, Aaron SD. Placebo effects in clinical trials evaluating patients with uncontrolled persistent asthma. Ann Am Thorac Soc. 2019;16(9):1124–1130. doi:10.1513/AnnalsATS.201901-071OC
   PubMed Web of Science ®Google Scholar
• Mokoka MC, McDonnell MJ, MacHale E, et al. Inadequate assessment of adherence to maintenance medication leads to loss of power and increased costs in trials of severe asthma therapy: results from a systematic literature review and modelling study. Eur Respir J. 2019;53(5):1802161. doi:10.1183/13993003.02161-2018
   PubMed Web of Science ®Google Scholar
• Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. doi:10.1183/13993003.00703-2018
   PubMed Web of Science ®Google Scholar
• Sverrild A, Hansen S, Hvidtfeldt M, et al. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2021. doi:10.1183/13993003.01296-2021
   PubMed Web of Science ®Google Scholar
• Emson C, Diver S, Chachi L, et al. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma. Respir Res. 2020;21(1):265. doi:10.1186/s12931-020-01513-x
   PubMed Web of Science ®Google Scholar
• Moorehead A, Hanna R, Heroux D, et al. A thymic stromal lymphopoietin polymorphism may provide protection from asthma by altering gene expression. Clin Exp Allergy. 2020;50(4):471–478. doi:10.1111/cea.13568
   PubMed Web of Science ®Google Scholar
• Corren J, Pham T-H, Gil EG, et al. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2021. doi:10.1111/all.15197
   Web of Science ®Google Scholar
• Pham T-H, Chen C, Colice G, Parnes JR, Griffiths JM, Cook B. Tezepelumab normalizes serum interleukin-5 and −13 levels in patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2021;127(6):689–691. doi:10.1016/j.anai.2021.08.008
   PubMed Web of Science ®Google Scholar
• Pham T-H, Cook B, Parnes JR, Colice G, Griffiths JM Tezepelumab reduces biomarkers of airway remodeling, MMP-10 and MMP-3: exploratory results from the phase 3 NAVIGATOR study. Abstract accepted for presentation at American Thoracic Society 2022 International Conference; May 13–18.
   Google Scholar
• Sridhar S, Zhao W, Pham T-H, et al. Tezepelumab decreases matrix remodelling and inflammatory pathways in patients with asthma. Eur Respir J. 2019;54(suppl 63):RCT3785. doi:10.1183/13993003.congress-2019.RCT3785
   Web of Science ®Google Scholar
• Menzies-Gow A, Ponnarambil S, Downie J, Bowen K, Hellqvist Å, Colice G. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21(1):279. doi:10.1186/s12931-020-01541-7
   PubMed Web of Science ®Google Scholar
• TEZSPIRE™ Prescribing information. Amgen Inc. and AstraZeneca AB; 2021. Available from: https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/e306dc06-d580-4457-b15f-9f28545ad63a/e306dc06-d580-4457-b15f-9f28545ad63a_viewable_rendition__v.pdf. Accessed January 28, 2021.
   Google Scholar
• Alpizar S, Megally A, Chen C, Raj A, Downie J, Colice G. Functionality and performance of an accessorized pre-filled syringe and an autoinjector for at-home administration of tezepelumab in patients with severe, uncontrolled asthma. J Asthma Allergy. 2021;14:381–392. doi:10.2147/JAA.S305114
   PubMed Web of Science ®Google Scholar
• Khusial RJ, Honkoop PJ, van der Meer V, Snoeck-Stroband JB, Sont JK. Validation of online asthma control questionnaire and asthma quality of life questionnaire. ERJ Open Res. 2020;6(1):00289–2019. doi:10.1183/23120541.00289-2019
   PubMedGoogle Scholar
• Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19(8):977–979. doi:10.1038/nm.3300
   PubMed Web of Science ®Google Scholar
• Brusselle G, Bracke K. Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(Suppl 5):S322–S328. doi:10.1513/AnnalsATS.201403-118AW
   PubMedGoogle Scholar
• Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. doi:10.1038/ni.3049
   PubMed Web of Science ®Google Scholar